On August 12, 2025, DermTech, Inc. went out of business as per its Chapter 11 liquidation filing under bankruptcy. DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.
Metrics to compare | DMTKQ | Peers Peers - average of corresponding metrics from companies closely matching DMTKQ: | Sector Sector - Average of metrics from a broad group of related Financials sector companies | Relationship RelationshipDMTKQPeersSector |
|---|---|---|---|---|
P/E Ratio | 0.0x | 0.0x | −0.6x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price / Book | 0.0x | 0.0x | 2.6x | |
Price / LTM Sales | 0.0x | 0.0x | 3.4x | |
Upside (Analyst Target) | 0.0% | 0.0% | 42.5% | |
Fair Value Upside | Unlock | 0.0% | 5.0% | Unlock |